Company research
AVITA Medical, Inc.
CIK 1762303Updated Sep 25, 2026
Name history
Avita Therapeutics, Inc. · through Dec 10, 2020Avita Medical, Ltd. · through Jun 30, 2020
RCEL price & chart
Loading TradingView…
NASDAQ:RCEL on TradingView ↗About the company
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.
In the news
Recent filings
S-8 filing
4/A filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 56,392,000Source | 79,711,000Source | 111,640,000Source | 98,264,000Source |
| Property, Plant and Equipment, NetUSD | 8,630,000Source | 10,018,000Source | 1,877,000Source | 1,200,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 5,645,000Source | 5,570,000Source | 487,000Source | 465,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,243,000Source | 14,050,000Source | 22,118,000Source | 18,164,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 9,086,000Source | 11,786,000Source | 7,664,000Source | 3,515,000Source |
| Inventory, NetUSD | 6,926,000Source | 7,269,000Source | 5,596,000Source | 2,125,000Source |
| Assets, CurrentUSD | 35,490,000Source | 57,000,000Source | 104,006,000Source | 87,458,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,293,000Source | 2,004,000Source | 1,659,000Source | 1,578,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,899,000Source | 3,571,000Source | 2,440,000Source | 851,000Source |
| Other Assets, NoncurrentUSD | 612,000Source | 546,000Source | 355,000Source | 122,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 73,042,000Source | 74,968,000Source | 61,891,000Source | 12,967,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 3,000Source | 3,000Source | 3,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 394,408,000Source | 367,568,000Source | 350,039,000Source | 339,825,000Source |
| Retained Earnings (Accumulated Deficit)USD | -408,401,000Source | -359,814,000Source | -297,969,000Source | -262,588,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,367,000Source | -1,939,000Source | -1,887,000Source | 7,627,000Source |
| Stockholders' Equity Attributable to ParentUSD | -16,650,000Source | 4,499,000Source | 49,056,000Source | 84,740,000Source |
| Liabilities and EquityUSD | 56,392,000Source | 79,711,000Source | 111,640,000Source | 98,264,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 62,677,000Source | 20,158,000Source | 13,199,000Source | 10,693,000Source |
| Operating Lease, Liability, CurrentUSD | 929,000Source | 900,000Source | 895,000Source | 612,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,135,000Source | 2,840,000Source | 1,702,000Source | 306,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 18,200,000Source | 35,900,000Source | — | — |
| Long-term Debt, Current MaturitiesUSD | 42,984,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 0Source | 42,245,000Source | 39,812,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,347,000Source | 1,126,000Source | 632,000Source | 568,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,519,000Source | 13,496,000Source | 8,384,000Source | 6,998,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 468,000Source | 2,160,000Source | 3,693,000Source | 371,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -31,195,000Source | -48,939,000Source | -38,011,000Source | -19,090,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 12,452,000Source | 37,363,000Source | 1,607,000Source | -19,332,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,005,000Source | 9,171,000Source | 1,381,000Source | 452,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 14,936,000Source | 3,508,000Source | 40,374,000Source | 900,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,807,000Source | -8,068,000Source | 3,954,000Source | -37,548,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 10,243,000Source | 14,050,000Source | 22,118,000Source | 18,164,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,980,000Source | 5,359,000Source | 1,143,000Source | 15,000Source |
| Income Taxes Paid, NetUSD | 15,000Source | 41,000Source | 44,000Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | -16,000Source | -26,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 9,519,000Source | 13,496,000Source | 8,384,000Source | 6,998,000Source |
| Amortization of Intangible AssetsUSD | 600,000Source | 93,000Source | 35,000Source | 58,000Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | 3,000,000Source | 3,000,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 18,200,000Source | 35,900,000Source | — | — |
| DepreciationUSD | 1,600,000Source | 1,000,000Source | 597,000Source | 510,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -17,000Source | -21,000Source | -37,000Source | 85,000Source |
| Gain (Loss) on Disposition of AssetsUSD | -595,000Source | -107,000Source | -83,000Source | -3,000Source |
| General and Administrative ExpenseUSD | 27,373,000Source | 33,195,000Source | 28,334,000Source | 23,330,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 0Source | 4,000Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 4,000Source | — |
| Income Tax Expense (Benefit)USD | 11,000Source | 54,000Source | 66,000Source | 36,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 4,000Source | — | -95,000Source | -426,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,587,000Source | -61,845,000Source | -35,381,000Source | -26,665,000Source |
| Operating ExpensesUSD | 101,350,000Source | 111,750,000Source | 86,446,000Source | 59,100,000Source |
| Other Nonoperating Income (Expense)USD | -1,038,000Source | 163,000Source | 8,483,000Source | — |
| Other Operating Income (Expense), NetUSD | — | — | 1,428,000Source | 3,215,000Source |
| Proceeds from Issuance of Common StockUSD | 14,792,000Source | — | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | 38,762,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 407,000Source | 2,135,000Source | 957,000Source | 900,000Source |
| Provision for Loan, Lease, and Other LossesUSD | -10,000Source | 23,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 70,879,000Source | 63,893,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 71,610,000Source | 64,251,000Source | 50,143,000Source | 34,421,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -42,534,000Source | -56,593,000Source | -42,655,000Source | -27,505,000Source |
| Other Nonoperating Income (Expense)USD | -1,038,000Source | 163,000Source | 8,483,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -48,576,000Source | -61,791,000Source | -35,315,000Source | -26,629,000Source |
| Income Tax Expense (Benefit)USD | 11,000Source | 54,000Source | 66,000Source | 36,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,587,000Source | -61,845,000Source | -35,381,000Source | -26,665,000Source |
| Earnings Per Share, BasicUSD per share | -1.74Source | -2.39Source | 1.4Source | 1.07Source |
| Earnings Per Share, DilutedUSD per share | -1.74Source | -2.39Source | 1.4Source | 1.07Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 27,860,784Source | 25,883,056Source | 25,331,264Source | 25,000,180Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 27,860,784Source | 25,883,056Source | 25,331,264Source | 25,000,180Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 600,000Source | 93,000Source | 35,000Source | 58,000Source |
| Current Income Tax Expense (Benefit)USD | 11,000Source | 54,000Source | 66,000Source | 36,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -17,000Source | -21,000Source | -37,000Source | 85,000Source |
| General and Administrative ExpenseUSD | 27,373,000Source | 33,195,000Source | 28,334,000Source | 23,330,000Source |
| Gross ProfitUSD | 58,816,000Source | 55,157,000Source | 42,363,000Source | 28,380,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -48,576,000Source | -61,778,000Source | -44,691,000Source | -26,764,000Source |
| Interest ExpenseUSD | 5,004,000Source | 5,361,000Source | 1,143,000Source | 16,000Source |
| Operating ExpensesUSD | 101,350,000Source | 111,750,000Source | 86,446,000Source | 59,100,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 1,428,000Source | 3,215,000Source |
| Research and Development ExpenseUSD | 20,839,000Source | 20,360,000Source | 20,821,000Source | 13,857,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 70,879,000Source | 63,893,000Source | — | — |
| Selling and Marketing ExpenseUSD | 53,138,000Source | 58,195,000Source | 37,291,000Source | 21,913,000Source |
Filing attachments
rcel-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) - AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the second quarter ended June 30, 2026. Second Quarter 202…
Read attachment ↗rcel-ex99_1.htm · 8-K · 2026-05-14
EX-99.1 2 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Reports First Quarter 2026 Financial Results VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) - AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates • Total revenue…
Read attachment ↗rcel-ex99_1.htm · 8-K · 2026-05-01
EX-99.1 3 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Names Cary Vance as Chief Executive Officer • Board appoints Cary Vance as President and Chief Executive Officer o Follows successful interim tenure and thorough search process by the Board • Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 - AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its Board of Direc…
Read attachment ↗